Table 2 Sensitivity for the HCC detection of Qliver, AFP, AFP-L3, DCP, and GALAD score across BCLC stages

Phase 1 plasma cohort

Qliver

62.50 (24.49–91.48)

[5/8]

85.71 (57.19–98.22)

[12/14]

96.77 (83.30–99.92)

[30/31]

AFP

37.50 (8.52–75.51)

[3/8]

28.57 (8.39–58.10)

[4/14]

58.06 (39.08–75.45)

[18/31]

AFPL3

50.00 (15.70–84.30)

[4/8]

28.57 (8.39–58.10)

[4/14]

45.16 (27.32–63.97)

[14/31]

DCP

25.00 (3.19–65.09)

[2/8]

71.43 (41.90–91.61)

[7/14]

67.74 (48.63–83.32)

[22/31]

GALAD

25.00 (3.19–65.09)

[2/8]

50.00 (23.04–76.96)

[7/14]

70.97 (51.96–85.78)

[22/31]

Phase 2 plasma cohort

Qliver

72.73 (39.03–93.98)

[8/11]

95.45 (77.16–99.88)

[21/22]

88.24 (72.55–96.70)

[30/34]

AFP

9.09 (0.23–41.28)

[1/11]

54.55 (32.21–75.61)

[21/22]

61.76 (43.56–77.83)

[30/34]

AFPL3

18.18 (2.28–51.78)

[2/11]

54.55 (32.21–75.61)

[12/22]

52.94 (35.13–70.22)

[18/34]

DCP

54.55 (23.38–83.25)

[6/11]

68.18 (45.13–86.14)

[15/22]

73.53 (55.64–87.12)

[25/34]

GALAD

18.18 (2.28–51.78)

[2/11]

68.18 (45.13–86.14)

[15/22]

67.65 (49.47–82.61)

[23/34]

Combined plasma cohort

Qliver

68.42 (43.45–87.42)

[13/19]

91.67 (77.53–98.25)

[33/36]

92.31 (82.95–97.46)

[60/65]

AFP

21.05 (6.05–45.57)

[4/19]

44.44 (27.94–61.90)

[16/36]

60.00 (47.10–71.96)

[39/65]

AFPL3

31.58 (12.58–56.55)

[6/19]

44.44 (27.94–61.90)

[16/36]

49.23 (36.60–61.93)

[32/65]

DCP

42.11 (20.25–66.50)

[8/19]

69.44 (51.89–83.65)

[25/36]

70.77 (58.17–81.40)

[46/65]

GALAD

21.05 (6.05–45.57)

[4/19]

61.11 (43.46–76.86)

[22/36]

69.23 (56.55–80.09)

[45/65]